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Résumé en
anglais
Resistance of transplanted mesenchymal stem cells (MSCs) in post-ischemic heart is
limited by their poor vitality. Vascular-endothelial-growth-factor-A (VEGF-A) as such
or slowly released by fibronectin-coated pharmacologically-active-microcarriers (FN-
PAM-VEGF) could differently affect survival kinases and anti-apoptotic mediator (e.g.
Bcl-2). Therefore VEGF-A or FN-PAM-VEGF could differently enhance cell
proliferation, and/or resistance to hypoxia/reoxygenation (H/R) of MSCs. To test
these hypotheses MSCs were incubated for 6-days with VEGF-A alone or with FN-
PAM-VEGF. In addition, MSCs pre-treated for 24-hrs with VEGF-A or FN-PAM-VEGF
were subsequently exposed to H/R (72-hrs 3% O(2) and 3-hrs of reoxygenation). Cell-
proliferation and post-hypoxic vitality were determined. Kinases were studied at 30-
min., 1- and 3-days of treatment. Cell-proliferation increased about twofold (P < 0.01)
6-days after VEGF-A treatment, but by a lesser extent (55% increase) with FN-PAM-
VEGF (P < 0.05). While MSC pre-treatment with VEGF-A confirmed cell-proliferation,
pre-treatment with FN-PAM-VEGF protected MSCs against H/R. In the early phase of
treatments, VEGF-A increased phospho-Akt, phospho-ERK-1/2 and phospho-PKCε
compared to the untreated cells or FN-PAM-VEGF. Afterword, kinase
phosphorylations were higher with VGEF, except for ERK-1/2, which was similarly
increased by both treatments at 3 days. Only FN-PAM-VEGF significantly increased
Bcl-2 levels. After H/R, lactate dehydrogenase release and cleaved Caspase-3 levels
were mainly reduced by FN-PAM-VEGF. While VEGF-A enhances MSC proliferation
in normoxia, FN-PAM-VEGF mainly hampers post-hypoxic MSC death. These
different effects underscore the necessity of approaches suited to the various
conditions. The use of FN-PAM-VEGF could be considered as a novel approach for
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